Pharmaleads 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases  1 Product   1 Trial   23 News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PL37 / Debiopharm
2013-004876-37: A study to assess the effectiveness and safety of PL37 in reducing pain intensity when given in addition to gabapentin or pregabalin in patients suffering from neuropathic pain of diabetic origin, for whom ongoing treatment with gabapentin or pregabalin does not provide complete or sufficient relief of their neuropathic pain.

Ongoing
2
40
Europe
PL37, PL37,
Pharmaleads SA, Pharmaleads SA
Neuropathic pain develops as a result of damage to, or dysfunction of, the system that normally signals pain. It may arise from a heterogeneous group of disorders that affect the peripheral and central nervous systems. People with neuropathic pain may experience altered pain sensation, areas of numbness or burning, and continuous or intermittent evoked or spontaneous pain. In this study, neuropathic pain of diabetic origin is being investigated.
 
 
IC 805 / Pharmaleads, IACTA Pharma
No trials found

Download Options